Efficacy and safety of glofitamab monotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma
10.3760/cma.j.cn115356-20241022-00156
- VernacularTitle:格菲妥单抗单药治疗复发难治弥漫大B细胞淋巴瘤的效果及安全性
- Author:
Yu WANG
1
;
Rong XIAO
;
Yan MAO
;
Xuemei YE
;
Boyue ZHENG
;
Hui LI
Author Information
1. 四川省人民医院（医疗集团）东篱医院血液科，成都 610000
- Keywords:
Lymphoma, large B-cell, diffuse;
Recidivism;
Refractory;
Glofitamab;
Prognosis;
Adverse effects
- From:
Journal of Leukemia & Lymphoma
2025;34(10):601-605
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of glofitamab in the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL).Methods:A retrospective case series study was performed. The clinical data of 11 patients with relapsed/refractory DLBCL who were treated with glofitamab in Sichuan Provincial People's Hospital from March 2024 to October 2024 were retrospectively analyzed. All patients received glofitamab monotherapy. Dose escalation was required in the first course, and glofitamab at a dose of 30 mg was administered from the second to the 12th course. The general data, clinical manifestations, laboratory examination results, Eastern Cooperative Oncology Group (ECOG) performance score, previous treatment history, therapeutic effect after medication and adverse reactions were collected.Results:Among 11 patients, there were 8 males and 3 females, with the median age [ M ( Q1, Q3)] of 60 (51, 76) years; 1 case was primary central nervous system DLBCL. The median number of prior treatment lines was 3 (2, 3) lines, and 6 cases received ≥3 lines of therapy; 1 case was double DLBCL and 3 cases was complicated with p53 mutations. The median follow-up time was 5 months (2-7 months). After treatment of the median number of glofitamab, 3 cases achieved complete remission, among which 1 case successfully bridged to autologous hematopoietic stem cell transplantation; 1 case had the stable disease and 7 cases achieved partial remission. Grade 1-2 adverse events included mild leukopenia in 3 patients, mild anemia in 4 patients, thrombocytopenia in 1 patient, and lymphopenia in 8 patients. Grade 3 hematologic adverse events included thrombocytopenia in 1 patient and severe lymphopenia in 1 patient. Non-hematological toxicities included mild rash in 1 patient, grade 1 liver dysfunction in 3 patients and inflammatory factor storm in 4 patients. No medication stop or deferral was found in patients due to severe adverse events. Conclusions:Glofitamab demonstrates a high response rate in the treatment of relapsed/refractory DLBCL, with manageable adverse events and a favorable safety.
